Champions Oncology (CSBR) Cash from Financing Activities (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Cash from Financing Activities of -$36000.0 in Q1 2026, down 121.43% quarter-over-quarter from $168000.0 in Q4 2025.
Champions Oncology (CSBR) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Champions Oncology's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$36000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to -$36000.0; the TTM figure through Jan 2026 stood at $86000.0 (down 47.88% YoY), while the FY2025 annual figure was $170000.0, up 132.26% from the prior year.
- Cash from Financing Activities was -$36000.0 for Q1 2026 at Champions Oncology, down from $168000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $239000.0 in Q4 2024 to a low of -$590000.0 in Q3 2023.
- Historically, Cash from Financing Activities has averaged -$10285.7 across 5 years, with a median of -$23000.0 in 2025.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities soared 221.43% in 2022, then plunged 568.75% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at $86000.0 in 2022, then soared by 55.81% to $134000.0 in 2023, then surged by 78.36% to $239000.0 in 2024, then decreased by 29.71% to $168000.0 in 2025, then sank by 121.43% to -$36000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$36000.0 (Q1 2026), $168000.0 (Q4 2025), and -$14000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 85,464.43 |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -36,000.00 |
| Jan 31, 2026 | -36,000.00 |
| Oct 31, 2025 | 168,000.00 |
| Oct 31, 2025 | 168,000.00 |
| Jul 31, 2025 | -14,000.00 |
| Jul 31, 2025 | -14,000.00 |
| Apr 30, 2025 | -32,000.00 |
| Apr 30, 2025 | -32,000.00 |
| Oct 31, 2024 | 239,000.00 |
| Oct 31, 2024 | 239,000.00 |
| Jul 31, 2024 | -37,000.00 |
| Jul 31, 2024 | -37,000.00 |
| Apr 30, 2024 | -37,000.00 |
| Apr 30, 2024 | -37,000.00 |
| Jan 31, 2024 | -34,000.00 |
| Jan 31, 2024 | -34,000.00 |
| Oct 31, 2023 | 134,000.00 |
| Oct 31, 2023 | 134,000.00 |
| Jul 31, 2023 | -590,000.00 |
| Jul 31, 2023 | -590,000.00 |